{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:14:07Z","timestamp":1792818847097,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Huntington-Krankheit (HK) ist eine autosomal-dominante Erbkrankheit, die zu motorischen, kognitiven und psychiatrischen Symptomen f\u00fchrt. Die Diagnose kann durch den molekulargenetischen Nachweis einer verl\u00e4ngerten CAG-Wiederholung im <jats:italic>Huntingtin<\/jats:italic>-Gen gesichert werden. Psychische und Verhaltenssymptome sind bei der HK h\u00e4ufig und k\u00f6nnen Jahre vor den motorischen Symptomen auftreten. Zu den psychiatrischen Symptomen geh\u00f6ren Apathie, Depression, Angst, Zwangssymptome und in einigen F\u00e4llen Psychosen und Aggression. Diese k\u00f6nnen aktuell nur symptomatisch behandelt werden, da sich krankheitsmodifizierende Therapieans\u00e4tze bei der HK noch in der Erprobung befinden. Die derzeitige klinische Praxis basiert auf Expertenmeinungen sowie Erfahrung mit der Behandlung \u00e4hnlicher Symptome bei anderen neurologischen und psychiatrischen Krankheiten. In diesem Artikel geben wir einen \u00dcberblick \u00fcber die komplexen psychischen Manifestationen der HK, die diagnostischen M\u00f6glichkeiten und die etablierten pharmakologischen und nichtpharmakologischen Behandlungsans\u00e4tze.<\/jats:p>","DOI":"10.1007\/s00115-024-01728-z","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:02:27Z","timestamp":1725022947000},"page":"871-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psychiatrische Symptome der Huntington-Krankheit","Psychiatric symptoms of Huntington\u2019s disease"],"prefix":"10.1007","volume":"95","author":[{"given":"Alzbeta","family":"M\u00fchlb\u00e4ck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolo Gabriele","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Marziniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Dose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"1728_CR1","volume-title":"The Medical and Surgical Reporter","author":"G Huntington","year":"1872","unstructured":"Huntington\u00a0G, Chorea\u00a0O (1872) The Medical and Surgical Reporter. S.W. Butler, Philadelphia"},{"issue":"6","key":"1728_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Huntington\u2019s disease Collaborative Research, G.","year":"1993","unstructured":"Huntington\u2019s disease Collaborative Research, G. (1993) A\u00a0novel gene containing a\u00a0trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72(6):971\u2013983","journal-title":"Cell"},{"issue":"10","key":"1728_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1212\/WNL.0b013e318249f683","volume":"78","author":"JM Lee","year":"2012","unstructured":"Lee\u00a0JM et\u00a0al (2012) CAG repeat expansion in Huntington disease determines age at onset in a\u00a0fully dominant fashion. Neurology 78(10):690\u2013695","journal-title":"Neurology"},{"issue":"6","key":"1728_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaneurol.2019.0423","volume":"76","author":"SL Gardiner","year":"2019","unstructured":"Gardiner\u00a0SL et\u00a0al (2019) Prevalence of Carriers of Intermediate and Pathological Polyglutamine Disease\u2013Associated Alleles Among Large Population-Based Cohorts. JAMA Neurol 76(6):650","journal-title":"JAMA Neurol"},{"issue":"9","key":"1728_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim\u00a0T et\u00a0al (2012) The incidence and prevalence of Huntington\u2019s disease: A\u00a0systematic review and meta-analysis. Mov Disord 27(9):1083\u20131091","journal-title":"Mov Disord"},{"issue":"1","key":"1728_CR6","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates\u00a0GP et\u00a0al (2015) Huntington disease. Nat Rev Dis Primers 1(1):15005","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1728_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi\u00a0SJ et\u00a0al (2022) A\u00a0biological classification of Huntington\u2019s disease: the Integrated Staging System. Lancet Neurol 21(7):632\u2013644","journal-title":"Lancet Neurol"},{"issue":"12","key":"1728_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/brainsci7060067","volume":"7","author":"R Paoli","year":"2017","unstructured":"Paoli\u00a0R et\u00a0al (2017) Neuropsychiatric Burden in Huntington\u2019s Disease. Brain Sci 7(12):67","journal-title":"Brain Sci"},{"key":"1728_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnagi.2014.00078","volume":"6","author":"Paulsen","year":"2014","unstructured":"Paulsen et\u00a0al (2014) Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A\u00a0Decade of the PREDICT-HD Study. Front Aging Neurosci 6:78","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"1728_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/jnnp-2011-301940","volume":"83","author":"JC Stout","year":"2012","unstructured":"Stout\u00a0JC et\u00a0al (2012) Evaluation of longitudinal 12 and 24\u00a0month cognitive outcomes in premanifest and early Huntington\u2019s disease. J\u00a0Neurol Neurosurg Psychiatry 83(7):687\u2013694","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1728_CR11","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1212\/NXG.0000000000000603","volume":"7","author":"JMM van der Burg","year":"2021","unstructured":"van der Burg\u00a0JMM et\u00a0al (2021) Effect of Body Weight on Age at Onset in Huntington Disease. Neurol Genet 7(4):e603","journal-title":"Neurol Genet"},{"key":"1728_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"AC Bachoud-L\u00e9vi","year":"2019","unstructured":"Bachoud-L\u00e9vi\u00a0AC et\u00a0al (2019) International Guidelines for the Treatment of Huntington\u2019s Disease. Front Neurol 10:710","journal-title":"Front Neurol"},{"issue":"Pt 4","key":"1728_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"HD Rosas","year":"2008","unstructured":"Rosas\u00a0HD et\u00a0al (2008) Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 131(Pt 4):1057\u20131068","journal-title":"Brain"},{"issue":"6","key":"1728_CR14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"J-P Vonsattel","year":"1985","unstructured":"Vonsattel\u00a0J\u2011P et\u00a0al (1985) Neuropathological Classification of Huntington\u2019s Disease. J\u00a0Neuropathol Exp Neurol 44(6):559\u2013577","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"1728_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/brain\/awq047","volume":"133","author":"DC Thu","year":"2010","unstructured":"Thu\u00a0DC et\u00a0al (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington\u2019s disease. Brain 133(4):1094\u20131110","journal-title":"Brain"},{"issue":"7","key":"1728_CR16","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/mds.27395","volume":"33","author":"S Mart\u00ednez-Horta","year":"2018","unstructured":"Mart\u00ednez-Horta\u00a0S et\u00a0al (2018) Structural and metabolic brain correlates of apathy in Huntington\u2019s disease. Mov Disord 33(7):1151\u20131159","journal-title":"Mov Disord"},{"issue":"1","key":"1728_CR17","first-page":"117","volume":"36","author":"DJ van Wamelen","year":"2013","unstructured":"van Wamelen\u00a0DJ et\u00a0al (2013) Suprachiasmatic nucleus neuropeptide expression in patients with Huntington\u2019s Disease. Sleep 36(1):117\u2013125","journal-title":"Sleep"},{"issue":"3","key":"1728_CR18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ana.25413","volume":"85","author":"MK Singh-Bains","year":"2019","unstructured":"Singh-Bains\u00a0MK et\u00a0al (2019) Cerebellar degeneration correlates with motor symptoms in Huntington disease. Ann Neurol 85(3):396\u2013405","journal-title":"Ann Neurol"},{"key":"1728_CR19","doi-asserted-by":"crossref","unstructured":"Dorsey ER (2013) Natural History of Huntington Disease. JAMA Neurol","DOI":"10.1001\/jamaneurol.2013.4408"},{"issue":"12","key":"1728_CR20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","volume":"85","author":"van Duijn","year":"2014","unstructured":"van Duijn et\u00a0al (2014) Neuropsychiatric symptoms in a\u00a0European Huntington\u2019s disease cohort (REGISTRY). J\u00a0Neurol Neurosurg Psychiatry 85(12):1411\u20131418","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1728_CR21","first-page":"Rrn1184","volume":"2","author":"M Orth","year":"2010","unstructured":"Orth\u00a0M et\u00a0al (2010) Observing Huntington\u2019s Disease: the European Huntington\u2019s Disease Network\u2019s REGISTRY. PLoS Curr 2:Rrn1184","journal-title":"PLoS Curr"},{"issue":"4","key":"1728_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JHD-180293","volume":"7","author":"KE Anderson","year":"2018","unstructured":"Anderson\u00a0KE et\u00a0al (2018) Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders. J\u00a0Huntingtons Dis 7(4):355\u2013366","journal-title":"J Huntingtons Dis"},{"issue":"19","key":"1728_CR23","doi-asserted-by":"publisher","first-page":"e2395","DOI":"10.1212\/WNL.0000000000011893","volume":"96","author":"B McAllister","year":"2021","unstructured":"McAllister\u00a0B et\u00a0al (2021) Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease. Neurology 96(19):e2395\u2013e2406","journal-title":"Neurology"},{"key":"1728_CR24","doi-asserted-by":"crossref","unstructured":"Jellinger KA (2024) The pathobiology of depression in Huntington\u2019s disease: an unresolved puzzle. J\u00a0Neural Transm","DOI":"10.1007\/s00702-024-02750-w"},{"issue":"4","key":"1728_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","volume":"19","author":"E van Duijn","year":"2007","unstructured":"van Duijn\u00a0E, Kingma\u00a0EM, van der Mast\u00a0RC (2007) Psychopathology in verified Huntington\u2019s disease gene carriers. J\u00a0Neuropsychiatry Clin Neurosci 19(4):441\u2013448","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1728_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jad.2019.03.043","volume":"250","author":"ZR Kachian","year":"2019","unstructured":"Kachian\u00a0ZR et\u00a0al (2019) Suicidal ideation and behavior in Huntington\u2019s disease: Systematic review and recommendations. J\u00a0Affect Disord 250:319\u2013329","journal-title":"J Affect Disord"},{"issue":"2","key":"1728_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1192\/bjp.bp.107.040113","volume":"192","author":"MK Nock","year":"2008","unstructured":"Nock\u00a0MK et\u00a0al (2008) Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry 192(2):98\u2013105","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1728_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41386-021-01109-z","volume":"47","author":"MM Kenwood","year":"2022","unstructured":"Kenwood\u00a0MM, Kalin\u00a0NH, Barbas\u00a0H (2022) The prefrontal cortex, pathological anxiety, and anxiety disorders. Neuropsychopharmacology 47(1):260\u2013275","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"1728_CR29","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.4088\/JCP.v69n1116","volume":"69","author":"van Duijn","year":"2008","unstructured":"van Duijn et\u00a0al (2008) Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington\u2019s disease compared with mutation-negative first-degree relatives. J\u00a0Clin Psychiatry 69(11):1804\u20131810","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1728_CR30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S2215-0366(16)30144-4","volume":"3","author":"CM Eddy","year":"2016","unstructured":"Eddy\u00a0CM, Parkinson\u00a0EG, Rickards\u00a0HE (2016) Changes in mental state and behaviour in Huntington\u2019s disease. Lancet Psychiatry 3(11):1079\u20131086","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"1728_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1176\/appi.neuropsych.20220033","volume":"35","author":"S Abdollah Zadegan","year":"2023","unstructured":"Abdollah Zadegan\u00a0S et\u00a0al (2023) Frequency and Pathophysiology of Apathy in Huntington Disease: A\u00a0Systematic Review and Meta-Analysis. J\u00a0Neuropsychiatry Clin Neurosci 35(2):121\u2013132","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"7","key":"1728_CR32","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/cercor\/bhj043","volume":"16","author":"R Levy","year":"2006","unstructured":"Levy\u00a0R, Dubois\u00a0B (2006) Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 16(7):916\u2013928","journal-title":"Cereb Cortex"},{"issue":"5","key":"1728_CR33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","volume":"14","author":"J Pagonabarraga","year":"2015","unstructured":"Pagonabarraga\u00a0J et\u00a0al (2015) Apathy in Parkinson\u2019s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 14(5):518\u2013531","journal-title":"Lancet Neurol"},{"issue":"9","key":"1728_CR34","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1002\/mds.28638","volume":"36","author":"AE De Paepe","year":"2021","unstructured":"De Paepe\u00a0AE et\u00a0al (2021) Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington\u2019s Disease. Mov Disord 36(9):2162\u20132172","journal-title":"Mov Disord"},{"issue":"5","key":"1728_CR35","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1017\/S1355617719000067","volume":"25","author":"MB Misiura","year":"2019","unstructured":"Misiura\u00a0MB et\u00a0al (2019) Apathy Is Related to Cognitive Control and Striatum Volumes in Prodromal Huntington\u2019s Disease. J\u00a0Int Neuropsychol Soc 25(5):462\u2013469","journal-title":"J Int Neuropsychol Soc"},{"issue":"8","key":"1728_CR36","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1017\/S0033291720000094","volume":"51","author":"SC Andrews","year":"2021","unstructured":"Andrews\u00a0SC et\u00a0al (2021) Apathy predicts rate of cognitive decline over 24\u00a0months in premanifest Huntington\u2019s disease. Psychol Med 51(8):1338\u20131344","journal-title":"Psychol Med"},{"issue":"1","key":"1728_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-180335","volume":"8","author":"M Oosterloo","year":"2019","unstructured":"Oosterloo\u00a0M et\u00a0al (2019) Obsessive-Compulsive and Perseverative Behaviors in Huntington\u2019s Disease. J\u00a0Huntingtons Dis 8(1):1\u20137","journal-title":"J Huntingtons Dis"},{"issue":"4","key":"1728_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JHD-190351","volume":"8","author":"R Hoffmann","year":"2019","unstructured":"Hoffmann\u00a0R et\u00a0al (2019) Obsessive-Compulsive Symptoms are Less Common in Huntington\u2019s Disease than Reported Earlier. J\u00a0Huntingtons Dis 8(4):493\u2013500","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"1728_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3233\/JHD-200397","volume":"9","author":"NE Karagas","year":"2020","unstructured":"Karagas\u00a0NE, Rocha\u00a0NP, Stimming\u00a0EF (2020) Irritability in Huntington\u2019s Disease. J\u00a0Huntingtons Dis 9(2):107\u2013113","journal-title":"J Huntingtons Dis"},{"key":"1728_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cortex.2019.06.012","volume":"120","author":"J Simpson","year":"2019","unstructured":"Simpson\u00a0J et\u00a0al (2019) Validity of irritability in Huntington\u2019s disease: A\u00a0scoping review. Cortex 120:353\u2013374","journal-title":"Cortex"},{"issue":"3","key":"1728_CR41","doi-asserted-by":"publisher","first-page":"e3335","DOI":"10.1002\/brb3.3335","volume":"14","author":"H Pardina-Torner","year":"2024","unstructured":"Pardina-Torner\u00a0H et\u00a0al (2024) Disentangling the neurobiological bases of temporal impulsivity in Huntington\u2019s disease. Brain Behav 14(3):e3335","journal-title":"Brain Behav"},{"key":"1728_CR42","doi-asserted-by":"publisher","first-page":"993357","DOI":"10.3389\/fnins.2022.993357","volume":"16","author":"DJ McLauchlan","year":"2022","unstructured":"McLauchlan\u00a0DJ, Linden\u00a0DEJ, Rosser\u00a0AE (2022) Excessive response to provocation rather than disinhibition mediates irritable behaviour in Huntington\u2019s disease. Front Neurosci 16:993357","journal-title":"Front Neurosci"},{"key":"1728_CR43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5334\/tohm.231","volume":"4","author":"E McCusker","year":"2014","unstructured":"McCusker\u00a0E, Loy\u00a0CT (2014) The many facets of unawareness in huntington disease. Tremor Other Hyperkinet Mov 4:257","journal-title":"Tremor Other Hyperkinet Mov"},{"issue":"2","key":"1728_CR44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/mdc3.12882","volume":"7","author":"M Rossi","year":"2020","unstructured":"Rossi\u00a0M et\u00a0al (2020) Nosology and Phenomenology of Psychosis in Movement Disorders. Mov Disord Clin Pract 7(2):140\u2013153","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"1728_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1517\/14656566.5.4.767","volume":"5","author":"RM Bonelli","year":"2004","unstructured":"Bonelli\u00a0RM, Hofmann\u00a0P (2004) A\u00a0review of the treatment options for Huntington\u2019s disease. Expert Opin Pharmacother 5(4):767\u2013776","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1728_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2217\/nmt.13.78","volume":"4","author":"F Cardoso","year":"2014","unstructured":"Cardoso\u00a0F (2014) Differential diagnosis of Huntington\u2019s disease: what the clinician should know. Neurodegen Dis Manage 4(1):67\u201372","journal-title":"Neurodegen Dis Manage"},{"issue":"1","key":"1728_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s42466-023-00292-2","volume":"5","author":"C Saft","year":"2023","unstructured":"Saft\u00a0C et\u00a0al (2023) Differential diagnosis of chorea (guidelines of the German Neurological Society). Neurol Res Pract 5(1):63","journal-title":"Neurol Res Pract"},{"issue":"2","key":"1728_CR48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group (1996) Unified Huntington\u2019s disease rating scale: Reliability and consistency. Mov Disord 11(2):136\u2013142","journal-title":"Mov Disord"},{"issue":"3","key":"1728_CR49","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ana.25171","volume":"83","author":"SL Mason","year":"2018","unstructured":"Mason\u00a0SL et\u00a0al (2018) Predicting clinical diagnosis in Huntington\u2019s disease: An imaging polymarker. Ann Neurol 83(3):532\u2013543","journal-title":"Ann Neurol"},{"key":"1728_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mcn.2019.02.004","volume":"97","author":"P Zeun","year":"2019","unstructured":"Zeun\u00a0P et\u00a0al (2019) Fluid and imaging biomarkers for Huntington\u2019s disease. Mol Cell Neurosci 97:67\u201380","journal-title":"Mol Cell Neurosci"},{"key":"1728_CR51","volume-title":"S2k-Leitlinie Chorea\/Morbus Huntington. Hrsg. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"C Saft","year":"2022","unstructured":"Saft\u00a0C et\u00a0al (2022) S2k-Leitlinie Chorea\/Morbus Huntington. Hrsg. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft f\u00fcr Neurologie (DGN)"},{"key":"1728_CR52","unstructured":"Gendiagnostikgesetz, Gesetz \u00fcber genetische Untersuchungen bei Menschen (Gendiagnostikgesetz \u2013 GenDG) vom 31.\u00a0Juli 2009 (BGBl.\u00a0I S.\u00a02529, 3672), das zuletzt durch Artikel\u00a015 Absatz\u00a04 des Gesetzes vom 4.\u00a0Mai 2021 (BGBl.\u00a0I S.\u00a0882) ge\u00e4ndert worden ist. 31.07.2009: Ein Service des Bundesministeriums der Justiz sowie des Bundesamts f\u00fcr Justiz \u2013 www.gesetze-im-internet.de."},{"issue":"3","key":"1728_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1399-0004.2012.01900.x","volume":"83","author":"R Macleod","year":"2013","unstructured":"Macleod\u00a0R et\u00a0al (2013) Recommendations for the predictive genetic test in Huntington\u2019s disease. Clin Genet 83(3):221\u2013231","journal-title":"Clin Genet"},{"issue":"1","key":"1728_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-023-02622-8","volume":"18","author":"A M\u00fchlb\u00e4ck","year":"2023","unstructured":"M\u00fchlb\u00e4ck\u00a0A et\u00a0al (2023) What we don\u2019t need to prove but need to do in multidisciplinary treatment and care in Huntington\u2019s disease: a\u00a0position paper. Orphanet J Rare Dis 18(1):19","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1728_CR55","doi-asserted-by":"publisher","first-page":"e0173872","DOI":"10.1371\/journal.pone.0173872","volume":"12","author":"H Gelderblom","year":"2017","unstructured":"Gelderblom\u00a0H et\u00a0al (2017) Bupropion for the treatment of apathy in Huntington\u2019s disease: A\u00a0multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE 12(3):e173872","journal-title":"PLoS ONE"},{"issue":"1","key":"1728_CR56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s42466-023-00285-1","volume":"5","author":"C Saft","year":"2023","unstructured":"Saft\u00a0C et\u00a0al (2023) Symptomatic treatment options for Huntington\u2019s disease (guidelines of the German Neurological Society). Neurol Res Pract 5(1):61","journal-title":"Neurol Res Pract"},{"issue":"1","key":"1728_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","volume":"22","author":"TB Stoker","year":"2022","unstructured":"Stoker\u00a0TB et\u00a0al (2022) Huntington\u2019s disease: diagnosis and management. Pract Neurol 22(1):32\u201341","journal-title":"Pract Neurol"},{"key":"1728_CR58","doi-asserted-by":"publisher","first-page":"Rrn1260","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"JM Burgunder","year":"2011","unstructured":"Burgunder\u00a0JM et\u00a0al (2011) An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington\u2019s Disease. PLoS Curr 3:Rrn1260","journal-title":"PLoS Curr"},{"issue":"2","key":"1728_CR59","doi-asserted-by":"publisher","first-page":"100200","DOI":"10.1016\/j.clinme.2024.100200","volume":"24","author":"TH Massey","year":"2024","unstructured":"Massey\u00a0TH, McLauchlan\u00a0DJ (2024) Huntington\u2019s disease: A\u00a0clinical primer for acute and general physicians. Clin Med 24(2):100200","journal-title":"Clin Med"},{"key":"1728_CR60","doi-asserted-by":"publisher","first-page":"105166","DOI":"10.1016\/j.neubiorev.2023.105166","volume":"149","author":"ML Clark","year":"2023","unstructured":"Clark\u00a0ML et\u00a0al (2023) A\u00a0systematic review and meta-analysis of depression and apathy frequency in adult-onset Huntington\u2019s disease. Neurosci Biobehav Rev 149:105166","journal-title":"Neurosci Biobehav Rev"},{"key":"1728_CR61","doi-asserted-by":"publisher","first-page":"Rrn1261","DOI":"10.1371\/currents.RRN1261","volume":"3","author":"K Anderson","year":"2011","unstructured":"Anderson\u00a0K et\u00a0al (2011) An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington\u2019s Disease. PLoS Curr 3:Rrn1261","journal-title":"PLoS Curr"},{"issue":"1","key":"1728_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s42466-023-00285-1","volume":"5","author":"C Saft","year":"2023","unstructured":"Saft\u00a0C et\u00a0al (2023) Symptomatic treatment options for Huntington\u2019s disease (guidelines of the German Neurological Society). Neurol Res Pract 5(1):61","journal-title":"Neurol Res Pract"},{"issue":"5","key":"1728_CR63","doi-asserted-by":"publisher","first-page":"e1001454","DOI":"10.1371\/journal.pmed.1001454","volume":"10","author":"J Barth","year":"2013","unstructured":"Barth\u00a0J et\u00a0al (2013) Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a\u00a0network meta-analysis. PLoS Med 10(5):e1001454","journal-title":"PLoS Med"},{"issue":"2","key":"1728_CR64","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JHD-210471","volume":"10","author":"FJR Eccles","year":"2021","unstructured":"Eccles\u00a0FJR et\u00a0al (2021) Experiences of Mindfulness-Based Cognitive Therapy for Premanifest Huntington\u2019s Disease. J\u00a0Huntingtons Dis 10(2):277\u2013291","journal-title":"J Huntingtons Dis"},{"key":"1728_CR65","volume-title":"Psychological interventions for people with Huntington\u2019s disease, Parkinson\u2019s disease, motor neurone disease, and multiple sclerosis: Evidence-based guidance","author":"JEF Simpson","year":"2021","unstructured":"Simpson\u00a0JEF, Zarotti\u00a0N, for British Psychological Society (2021) Psychological interventions for people with Huntington\u2019s disease, Parkinson\u2019s disease, motor neurone disease, and multiple sclerosis: Evidence-based guidance. Lancaster University"},{"issue":"2","key":"1728_CR66","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3233\/JHD-210516","volume":"11","author":"TM Petzke","year":"2022","unstructured":"Petzke\u00a0TM, Rodriguez-Girondo\u00a0M, van der Meer\u00a0LB (2022) The Hold me Tight Program for Couples Facing Huntington\u2019s Disease. J\u00a0Huntingtons Dis 11(2):203\u2013215","journal-title":"J Huntingtons Dis"},{"issue":"3","key":"1728_CR67","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JHD-220532","volume":"11","author":"U Jones","year":"2022","unstructured":"Jones\u00a0U, Kegelmeyer\u00a0DA, Kloos\u00a0AD (2022) Implementing Physiotherapy Huntington\u2019s Disease Guidelines in Clinical Practice. J\u00a0Huntingtons Dis 11(3):307\u2013311","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"1728_CR68","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12904-023-01171-y","volume":"22","author":"DJ Boersema-Wijma","year":"2023","unstructured":"Boersema-Wijma\u00a0DJ et\u00a0al (2023) Palliative care in advanced Huntington\u2019s disease: a\u00a0scoping review. BMC Palliat Care 22(1):54","journal-title":"BMC Palliat Care"},{"issue":"7","key":"1728_CR69","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1089\/jpm.2022.0160","volume":"26","author":"LL Sokol","year":"2023","unstructured":"Sokol\u00a0LL et\u00a0al (2023) Death Anxiety in Huntington Disease: Longitudinal Heath-Related Quality-of-Life Outcomes. J\u00a0Palliat Med 26(7):907\u2013914","journal-title":"J Palliat Med"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01728-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-024-01728-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01728-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T13:04:34Z","timestamp":1725455074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-024-01728-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1007\/s00115-024-01728-z","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"30 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>P.\u00a0Brieger<\/b>: A. Finanzielle Interessen: P. Brieger gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: \u00c4rztlicher Direktor des kbo-Isar-Amper-Klinikums, M\u00fcnchen | Mitgliedschaft: DGPPN. <b>M.\u00a0Dose<\/b>: A. Finanzielle Interessen: Reisekosten f\u00fcr Leitung von Gruppen bei Jahrestagungen der Deutschen Huntington-Hilfe (DHH e.V.). \u2013 kbo (Kliniken des Bezirks Oberbayern) Fachberater f\u00fcr Autismus-Spektrum-St\u00f6rungen bei Erwachsenen und Huntington-Krankheit. \u2013 B. Nichtfinanzielle Interessen: kbo (Kliniken des Bezirks Oberbayern) Fachberater f\u00fcr Autismus-Spektrum-St\u00f6rungen bei Erwachsenen und Huntington-Krankheit | Mitglied des wissenschaftlichen Beirats der Deutschen-Huntington-Hilfe\/DHH e.V. und von Autismus Deutschland, Mitglied des Europ\u00e4ischen Huntington Netzwerkes (EHDN) und der DGPPN. <b>R.\u00a0Hoffmann<\/b>: A. Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Pr\u00fcfer in Studien f\u00fcr Hoffmann-LaRoche, Wave, SOM-Tech, Prilenia und CHDI. \u2013 B. Nichtfinanzielle Interessen: Angestellter Oberarzt Huntington-Zentrum-S\u00fcd, kbo-Isar-Amper-Klinikum, Region M\u00fcnchen, Taufkirchen (Vils). <b>M.\u00a0Marziniak<\/b>: A. Finanzielle Interessen: M. Marziniak gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Angestellt als Chefarzt der Klinik f\u00fcr Neurologie am Isar-Amper-Klinikum, 85540 Haar seit 2013 | Mitgliedschaften: DGN, DMSG, DGKN, DSG, DGSS | Mitgliedschaft und bis Ende 2021 2. Vizepr\u00e4sident der DMKG. <b>A. M\u00fchlb\u00e4ck<\/b>: A. Finanzielle Interessen: Meine Institution wurde f\u00fcr meine Rolle als Hauptpr\u00fcferin in Studien f\u00fcr Hoffmann- LaRoche, Wave, SOM-Tech, Prilenia und die Cure Huntington\u2019s Disease Initiative Foundation (CHDI) bezahlt. Bis 2023 arbeitete ich am Huntington-Zentrum der Neurologischen Klinik der Universit\u00e4t Ulm, diese Einrichtung erhielt Zuwendungen f\u00fcr klinische Studien von Hoffmann-LaRoche, Ionis-Pharma, Prilenia, Novartis, TEVA und PTC-Therapeutics. Ich habe an der Universit\u00e4t Ulm (unter der Leitung von Prof. Landwehrmeyer) an EU-Forschungsprojekten (Horizon 2020, JPND 2018) teilgenommen, die vom Bundesministerium f\u00fcr Bildung und Forschung (BMBF) finanziert wurden. \u2013 Ich habe Reise- und \u00dcbernachtungskosten erstattet bekommen von European Huntington Association (EHA), Europ\u00e4ischen Huntington Netzwerk (EHDN), der Deutschen Huntington Hilfe (DHH), der Deutschen Heredoataxie Gesellschaft (DHAG), der Deutschen Parkinson Gesellschaft (DPG) und der Firma Gen.Orph erstattet. \u2013 B. Nichtfinanzielle Interessen: F\u00c4, Huntington-Zentrum, Neurologie, Uniklinik Ulm, Ulm (Teilzeit 2017 -2023); O\u00c4, Huntington-Zentrum S\u00fcd, kbo-Isar-Amper-Klinikum, Klinik Taufkirchen, Taufkirchen (Teilzeit 2020 bis dato ); F\u00c4, Psychiatrie, Klinikum re. d. Isar, TUM, M\u00fcnchen (Teilzeit 03\/2024 bis dato ) | Mitgliedschaften: European Huntington Association (EHA), Deutsche Parkinson Gesellschaft (DPG), Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) | Mitglied des Wissenschaftlichen Beirats - Deutsche Huntington Hilfe (DHH), Vorstandsmitglied - Europ\u00e4ischen Huntington Netzwerk (EHDN), Vorstandsmitglied - Deutsche Heredoataxie Gesellschaft (DHAG). <b>N.\u00a0Pozzi<\/b>: A. Finanzielle Interessen: N. Pozzi wurde gef\u00f6rdert von Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)\u2014Project-ID 424778381\u2014TRR 295. \u2013 B. Nichtfinanzielle Interessen: Angestellter Arzt in Weiterbildung im Huntington-Zentrum-S\u00fcd, kbo-Isar-Amper-Klinikum, Region M\u00fcnchen, Taufkirchen (Vils) und in Neurologische Klinik und Poliklinik, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg. <b>J.\u00a0Priller<\/b>: A. Finanzielle Interessen: Studienteilnahme: EHDN, CHDI, Ionis\/Roche, Ergomed. \u2013 Reisekosten: EHDN, CHDI. \u2013 Kein Interessenkonflikt durch wissenschaftliche Zusammenarbeit mit Neurimmune und Beratert\u00e4tigkeit bei Axon. \u2013 Patent auf EPO-Varianten. \u2013 B. Nichtfinanzielle Interessen: \u00c4rztlicher Direktor, Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie, Klinikum rechts der Isar, School of Medicine and Health, TU M\u00fcnchen, M\u00fcnchen; Leiter, Labor f\u00fcr Mol. Psychiatrie, Neuropsychiatrie, Charit\u00e9 - Universit\u00e4tsmedizin Berlin; PI, DZNE Berlin und DZPG M\u00fcnchen; Chair of Brain Inflammation and Repair, University of Edinburgh and UK DRI | Kein direkter Interessenkonflikt durch Mitgliedschaften in der Deutschen Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), der Deutschen Gesellschaft f\u00fcr Gerontopsychiatrie und -psychotherapie (DGGPP), der Deutschen Gesellschaft f\u00fcr Biologische Psychiatrie (DGBP), dem Deutschen Zentrum f\u00fcr Neurodegenerative Erkrankungen (DZNE) und Deutschen Zentrum f\u00fcr Psychische Gesundheit (DZPG), dem Deutschen Netzwerk Ged\u00e4chtnisambulanzen (DNG), Generate e.V. und der International Group for The Study of Lithium Treated Patients (IGSLI).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}